Primary Posterior Tracheopexy Prevents Tracheal Collapse
Launched by UMC UTRECHT · Mar 21, 2024
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Rationale:
A congenital blind-ending gullet (oesophagus), or Oesophageal Atresia (OA), is very often accompanied by a weakened windpipe (trachea). This is known as tracheomalacia (TM) and entails that the windpipe collapses during expiration. Severe TM can cause increased respiratory morbidity, including frequent respiratory tract infections and blue spells, that can potentially progress to respiratory arrest. Respiratory morbidity poses a significant burden on OA patients, both in the short term and over the course of long-term follow-up. When severe TM is identified, surgical interventio...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a confirmed diagnosis of OA with a distal TOF
- • Tracheomalacia
- • Written informed consent by both parents or legal representatives
- Exclusion Criteria:
- • Patients with OA without a distal TOF
- • Premature neonates \<34 weeks
- • Endotracheal tube size \< 3.0
- • Cormack score 3 or 4 as scored by either the otolaryngologist, anesthesiologist, or neonatal/pediatric intensive care specialist
- • Patients with a cyanotic cor vitium
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, , Netherlands
London, , United Kingdom
Rotterdam, , Netherlands
Patients applied
Trial Officials
John Vlot, MD, PhD
Principal Investigator
Erasmus Medical Center
Jan F Svensson, MD, PhD
Principal Investigator
Karolinska University Hospital
Colin Butler, MD, PhD
Principal Investigator
Great Ormond Street Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported